It has been clearly demonstrated that left ventricular (LV) hypertrophy is a strong blood pressure independent risk factor for cardiovascular morbidity and mortality in the general population, in primary and secondary hypertension and in cardiac patients. LV hypertrophy in arterial hypertension develops in response to an increased afterload, but underlying pathophysiological mechanisms include a variety of non-haemodynamic factors. Due to the prognostic importance of LV hypertrophy, normalisation of LV mass emerged as a desirable goal of antihypertensive treatment. Indeed, several prospective studies now indicate that regression of LV hypertrophy reduced cardiovascular complications. As a consequence, the question was raised whether certain antihypertensive drugs
Introduction
Left ventricular (LV) hypertrophy has been clearly established to be a strong, blood pressure independent risk factor for cardiovascular morbidity and mortality. [1] [2] [3] A report from the Framingham Heart Study documented that LV mass strongly predicted all-cause and cardiac death and coronary heart disease events in adults over age 40 and noted that only LV mass index and age were strong and consistent predictors of all three outcome events in all age and sex subgroups. 1 These results suggest that echocardiographic LV mass summarises the integrated adverse effects on the heart of increased haemodynamic load and vascular damage and, when elevated, predisposes directly to complications. Mechanisms of such predisposition may include enhancement of the extent and rapidity of development of myocardial infarction 4, 5 and risk of sudden death following myocardial infarction. 6 Reduced coronary flow reserve secondary to increased basal demand and/or altered microvascular function has been documented in hypertensive LV hypertrophy. 7 Another mechanism by which LV hypertrophy may predispose to cardiac morbidity is by induction of electrophysiological abnormalities and consequently of arrhythmias. LV mass has been shown to 9 Cardiac adaptation to increased pressure load which clinically presents as an increase in LV mass is influenced by various physiological and pathological stimuli. In addition, other haemodynamic and non-haemodynamic determinants represent important contributing factors for cardiac structural adaptative processes. Therefore, the concept that various antihypertensive agents may affect LV hypertrophy differently due to their disparate effects on non-haemodynamic factors resulted in numerous studies. Prevalence, determinants, prognosis, and treatment of LV hypertrophy is discussed in this article with a focus on reversal of LV hypertrophy by different antihypertensive drugs.
Prevalence of left ventricular hypertrophy in human hypertension
In studies of mild to moderate essential hypertension, 3-8% of patients had LV hypertrophy by electrocardiography. In contrast, LV hypertrophy is found in 12-30% of unselected hypertensive adults by echocardiography. [10] [11] [12] Although LV hypertrophy is not present in all hypertensive patients, its prevalence may exceed 90% among patients with sustained severe or malignant hypertension 13, 14 as opposed to only 10% of patients with new onset of malignant hypertension or pre-eclampsia. 14, 15 Coexisting obesity has been shown to increase the prevalence of hypertensive LV hypertrophy by 1.5-to 2-fold. 3, 16 Hammond et al 3 demonstrated that in a population of employed normotensive and hypertensive individuals, body mass index, height, and systolic blood pressure were independent predictors of LV mass. In patients with essential hypertension, Schmieder et al 17 found that obesity per se is associated with increased LV mass, particularly with an eccentric pattern of LV hypertrophy. The prevalence of LV hypertrophy in secondary forms of hypertension due to renovascular or endocrinological disease is similar to that in essential hypertension. 18, 19 Racial differences have also been observed. In elderly hypertensive patients LV hypertrophy was more common in black (73%) than in Hispanic hypertensive subjects (53%), with white individuals in the intermediate range (60%). 20 In patients with essential hypertension, dietary salt intake emerged as a strong and independent determinant of LV hypertrophy in addition to blood pressure and obesity. 21 Thus, it can be assumed that LV hypertrophy is more prevalent in populations with high salt intake. Other factors contributing to LV hypertrophy include anaemia in hypertensive patients with endstage renal disease 22 and alcohol consumption as an independent determinant of LV hypertrophy. 23 Male gender was also reported to have an influence on LV mass. 24 However, Kupari et al 25 found that sexspecific effects disappeared when the different haemodynamic, lifestyle, and laboratory characteristics for men and women were included in the statistical analysis.
Determinants of left ventricular hypertrophy
The pathophysiological mechanisms underlying LV hypertrophy have been subject to numerous studies focusing on haemodynamic factors, including increased blood pressure, wall stress, preload, and arterial stiffness of large conduit arteries. With respect to non-haemodynamic contributors, genetic factors, activation of the sympathetic nervous system, and regulation of the renin-angiotensinaldosterone system were examined.
The impact of blood pressure on LV hypertrophy has been clearly demonstrated by ambulatory blood pressure monitoring. LV mass and relative wall thickness are related more closely to 24-h ambulatory blood pressure than to casual blood pressure. [26] [27] [28] LV mass has been shown to be related more closely to systolic than to diastolic blood pressure, 26, 29, 30 whereas the opposite was true for LV wall thickness and relative wall thickness. 26, 30 An increased enddiastolic volume of the left ventricle by volume overload leads to eccentric hypertrophy. 31 In contrast, pure pressure overload results in an increased LV wall thickness without concomitant increase in cavity volume ('concentric hypertrophy'). Increased arterial stiffness of large conduit arteries, 29, 32 increased pulse wave velocity (with reflecting waves meeting an open aortic valve), and blood viscosity 33, 34 represent other haemodynamic factors that may modify LV hypertrophy in arterial hypertension.
Evidence from the last few years has advanced our understanding of the contribution of non-haemodynamic factors to LV hypertrophy with special emphasis on the sympathetic nervous system, the renin-angiotensin-aldosterone system, and genetic factors. There have been conflicting results on the role of the sympathetic nervous system. Administration of catecholamines in vivo induced LV hypertrophy, 35, 36 but did not induce hypertrophy of cultured adult myocardial cells in vitro. 37 Whether increased neurogenic neural activity of the central sympathetic nervous system itself contributes to LV hypertrophy independently of other factors warrants further investigation.
There exists increasing evidence that the reninangiotensin-aldosterone system contributes to the development of LV hypertrophy. In cell culture experiments and animal models, cardiotrophic effects of angiotensin II are well documented. 38, 39 Angiotensin II has been shown to correlate with LV structural parameters in humans. 40 The hypothesis that angiotensin II exerts growth stimulating effects is supported by several studies. High concentration of angiotensin II in relation to the rate of sodium excretion has been demonstrated to be associated with exaggerated LV hypertrophy in essential hypertension. 41 In young normotensive and mildly hypertensive patients, relatively high angiotensin II concentrations after high oral salt intake correlated with LV mass independent of ambulatory blood pressure in the hypertensive subjects. 42 An exaggerated increase of blood pressure in response to infusion of angiotensin II was shown to be related to an increased LV mass in young hypertensive subjects independent of blood pressure. 43 These results suggest that in human essential hypertension inadequate suppression of angiotensin II and/or hyperresponsiveness to angiotensin II modulate LV structural changes to increased pressure load. This notion is further supported by therapeutic studies demonstrating an excessive decrease of LV mass in hypertensive patients when angiotensin II synthesis or AT 1 receptors were blocked. 44, 45 In experiments, aldosterone has been found to increase collagen content in the myocardium. 46 Chronic inappropriate high concentrations of aldosterone have been described to be associated with a fibrous tissue response in both the left and right ventricle, 46 ,47 thereby suggesting that morphological adaptation of the left ventricle in hypertensive heart disease and structural remodelling of both ventricles is influenced by aldosterone. In humans inappropriate high aldosterone concentrations (after suppression with high dietary salt intake) are related to an increased echocardiographic LV mass and impaired LV systolic function in hypertensive subjects independent of 24-h ambulatory blood pressure. 48 Therefore, aldosterone seems to affect LV structure and function in human hypertension.
Different authors investigated possible genetic factors contributing to LV hypertrophy. Ravogli et al 28 found an increased LV mass in normotensive offspring of hypertensive parents. Other studies documenting a possible genetic factor include twin studies 49, 50 and racial studies comparing white and black hypertensive patients. These studies indicate that the greater cardiac hypertrophy found in black individuals parallels the higher frequency and severity of hypertension in blacks, 51, 52 suggesting that race per se is not a determinant of LV hypertrophy.
Prognosis of left ventricular hypertrophy
Numerous studies revealed a close relation between LV hypertrophy and the risk of cardiovascular morbidity and mortality not only in primary hypertension but also in the general population. 1 In a study of Koren et al, 2 patients with essential hypertension and LV hypertrophy had a higher incidence of cardiovascular events during 10 years of follow-up than those without LV hypertrophy. Different studies in secondary hypertension found that the presence of LV hypertrophy predicted death in hypertensive patients with end-stage renal disease independent of other factors. [53] [54] [55] An increased risk for cardiovascular morbid events in patients suffering from coronary artery disease has also been related to the presence of LV hypertrophy. The survival rate in patients with coronary heart disease and LV hypertrophy was decreased compared with the survival rate in those with no evidence of LV hypertrophy. 56 In an elderly, unselected population, Aronow et al 57 found that during a follow-up of 27 months the incidence of new cardiac events and of atherothrombotic brain infarction was significantly higher in patients with an echocardiographically determined increase in LV mass than in patients with normal LV mass. Cooper et al 58 found that LV mass as estimated by echocardiography is a powerful prognostic factor independent of ejection fraction and obstructive coronary disease, with the thickness of the ventricular septum and the posterior wall being even more highly predictive of a fatal outcome.
Not only increased LV mass but also LV geometry is of prognostic importance. In patients with primary hypertension, it was demonstrated that hypertensive subjects with concentric LV hypertrophy are characterised by a higher incidence of cardiovascular events than hypertensive subjects with eccentric LV hypertrophy. 2, 55 In elderly hypertensive black and white patients, the incidence of coronary events with concentric LV hypertrophy was higher than in those with eccentric hypertrophy. 59 In contrast, an eccentric pattern of LV hypertrophy in uraemic cardiomyopathy was even more closely related to cardiovascular mortality than LV mass per se, pointing to the importance of LV geometry for prognosis in end-stage renal disease. 55 Thus, both LV hypertrophy and geometry are of major importance for cardiovascular prognosis in hypertensive patients. Similarly, in this study population, impaired systolic function was most predictive, which is not surprising since low ejection fraction indicates congestive heart failure.
Reversal of left ventricular hypertrophy
Prospective studies now indicate that reversal of LV hypertrophy appears to be a desirable therapeutic
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Non-pharmacological intervention
Several non-pharmacological interventions have been shown to lower blood pressure. Weight reduction, for example, has been shown to lower blood pressure in obese patients. 64, 65 Additionally, MacMahon et al 64 found that weight reduction was directly associated with reduced LV mass in overweight hypertensive patients independent of changes in blood pressure. Most interestingly, in mildly obese and hypertensive subjects, a greater decrease in LV mass by weight loss than by treatment with ␤-blockers has also been demonstrated. 65 In accordance, intensive nutritional hygienic intervention leading to sustained weight reduction has been shown to decrease LV mass. 66 Although salt restriction has been shown to reduce LV mass in hypertension, the concomitant fall in blood pressure could be held responsible for these effects on LV hypertrophy. 67 However, in the large-scale prospective Treatment of Mild Hypertension Study (TOMHS), 68 salt reduction emerged as an effective and blood pressure independent measure to reduce LV mass.
In addition to a blood pressure rising effect, excessive alcohol intake seems to increase LV mass. 23 Although no prospective studies addressing the ability of alcohol moderation to reduce LV mass are available at this time, alcohol consumption should be avoided or reduced to a minimum in hypertensive patients with LV hypertrophy, since alcohol consumption beyond certain limits (approximately 40 g/day) increases blood pressure and increases the risk of ventricular arrhythmias in patients with LV hypertrophy.
Several studies found that regular exercise can result in satisfactory blood pressure control, 69 but no reduction in echocardiographic LV mass was observed under regular exercise. However, the pattern of LV hypertrophy may change from concentric towards eccentric LV hypertrophy and from fetal abnormal myosin isoform pattern to the physiological adult composition in the myocardium.
Taken together, non-pharmacological intervention seems to be beneficial not only in reducing blood pressure but also in excess to its blood pressure lowering effects in decreasing LV hypertrophy, particularly when adjusted to an individual's risk profile.
Antihypertensive drug treatment in primary hypertension
Far more than 500 clinical trials in patients with arterial hypertension have been carried out to answer the question whether different hypertensive drugs differ in their ability to reduce ventricular hypertrophy. Results from these studies are inconsistent and vary in a large extent. However, if blood pressure was reduced substantially, LV mass decreased by treatment with almost all classes of antihypertensive drugs. Therefore, sustained blood pressure control seems to be of crucial importance 63 cardiovascular morbid events to achieve reduction of LV hypertrophy in hypertensive patients.
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Large scale studies certainly are more satisfactory than meta-analyses to delineate conclusions on which antihypertensive agent in more capable of reducing LV hypertrophy. However, meta-analysis is helpful in increasing statistical power, resolving uncertainty when results differ between studies, and improving accurate estimation of the magnitude of effect. The most critical issue with regard to metaanalyses is the methodologic and scientific quality of the studies to be combined, since reliability of resulting conclusions of meta-analyses depends on the methods used in the original studies. 70 Therefore, the quality of a meta-analysis indeed depends on the quality of those studies included. So far, four meta-analyses [71] [72] [73] [74] and an updated version of the original meta-analysis 75 have been carried out in order to assess the effects of different antihypertensive drugs on reversal of LV hypertrophy.
In a first meta-analysis 71 comprising 104 studies with a total of 2107 patients covering the publication period until 1990 including the four major drug classes (angiotensin-converting enzyme (ACE)-inhibitors, calcium channel blockers, ␤-blockers and diuretics), ␣-blockers, alpha-methyldopa, vasodilators, and combination therapy, the changes in LV mass were analysed. The combined results of all active treatments differed significantly from placebo, suggesting an overall effect of antihypertensive treatment on reduction of LV mass. In this metaanalysis, ACE-inhibitors emerged as the most potent drug class in reducing LV mass, followed by alphamethyldopa and alpha-blockers. Calcium channel blockers (non-dihydropyridines) were more effective than ␤-blockers, and diuretics were in the intermediate range. Changes in posterior wall thickness and interventricular septal wall thickness in response to antihypertensive drug treatment were not significantly different between drug classes but showed similar trends to those observed for LV mass.
Another meta-analysis comprised a total of 109 treatment studies published in the same period and included a total of 2357 patients with an average age of 49 years. 72 The average follow-up of patients was 10.1 months, but 56% of studies had a follow-up shorter than 6 months. Antihypertensive drug treatment was shown to be effective in reducing LV mass with an overall reduction in mean arterial pressure by 14.9% (95% CI: 14.0-15.8) in parallel with a reduction in LV mass of 11.9% (95% CI: 10.1-13.7). From the different drug classes ACE-inhibitors (−15%) emerged as most effective in reducing LV mass followed by diuretics (−11.3%), calcium channel blockers (−8.5%), and ␤-blockers (−8%). Although reduction in blood pressure was similar for all antihypertensive agents, the correlation between changes in mean arterial pressure and effect on LV mass was only significant for ␤-blockers, indicating that no blood pressure independent effects could be claimed for ␤-blockers. Reduction in LV mass was mainly due to a decrease in LV wall thickness, except for diuretics with a predominant reduction in LV diameter. Conclusively, these results pointed to an effect of antihypertensive therapy on regression of LV hypertrophy that was most pronounced with ACE inhibitors.
A meta-analysis by Jennings and Wong 73 comprised publication from the end of 1990 to the end of 1995 and included a total number of 1896 patients. Although the quality of the studies included had slightly improved, with larger sample sizes and more stringent attention to study design compared with previous meta-analyses, 50% of the study arms had fewer than 20 subjects in each trial arm. Overall, the five classes of drugs lowered blood pressure to the same extent. The greatest change in LV mass regression was found to be associated with the greatest blood pressure reduction overall. After correction for blood pressure, the rank order with respect to LV mass reduction was ␣-blockers, ACE-inhibitors, calcium antagonists, diurectics, lifestyle changes and ␤-blockers. The authors concluded that LV hypertrophy regression does occur with present therapies and is more evident with ACE-inhibitors, calcium antagonists, and perhaps ␣-blockers.
The meta-analysis by Schmieder et al 74 only included double-blind, randomised, controlled clinical studies with parallel group design. Out of a large sample size of 471 studies identified by extensive literature search, only 39 studies of presumably high scientific quality, published until July 1995, fulfilled the preset inclusion criteria. In the final analysis of studies, 1394 patients, with 189 in the placebo arm and 1205 in the active treatment arm, were included. Decline in blood pressure, pretreatment LV mass, duration of antihypertensive pharmacologic therapy, and antihypertensive drug class emerged as independent determinants for the reduction of LV mass. After adjustment for different durations of treatment, significant differences were observed for different drug classes in reduction of LV mass and posterior wall thickness. Direct comparisons revealed that ACE-inhibitors effected a greater decrease in LV mass index than diuretics and ␤-blockers. No significant difference was found between ACE-inhibitors and calcium channel blockers.
Due to the fact that within the last years several studies have been carried out with respect to regression of LV hypertrophy, an updated version of the aforementioned meta-analysis has been performed. 75 Thirteen controlled clinical studies with a double-blind, randomised, parallel group design published until December 1996 were evaluated in addition to the previous one.
76 -87 Data of all 50 studies comprised a total of 1715 patients with essential hypertension, 165 (age: 50 ± 3 years) in the placebo arm and 1550 subjects (age: 56 ± 10 years) in the active treatment arm with one of the four major antihypertensive drug classes.
Overall, the greater the decline in systolic blood pressure (r = 0.27; P Ͻ 0.05), the longer duration of therapy (r = 0.38; P Ͻ 0.001), and the higher the pretreatment value of LV mass index (r = 0.53; P Ͻ 0.001), the more marked was the decrease of LV mass index. At similar pretreatment LV mass clinical characteristics (age, body mass index . . .) and fall in systolic and diastolic blood pressure as well as duration, ACE inhibitors reduced LV mass by 12% (95% CI: 9.0%-14.5%), calcium channel blockers by 11% (95% CI: 7.8%-13.7%), ␤-blockers by 5% (95% CI: 1.2%-7.3%), and diuretics by 8% (95% CI: 3.9%-11.1%). Differences for LV wall thickness were similar. After Bonferroni correction (P Ͻ 0.05), ACE-inhibitors and calcium channel blockers were more effective in reducing LV mass than ␤-blockers and emerged as the most potent drug classes for treating LV hypertrophy in essential hypertension (Figure 1 ).
Prognosis after reduction of left ventricular hypertrophy
There is increasing evidence that reversal of LV hypertrophy is associated with improved cardiovascular prognosis (Table 1) . Although data from the Framingham study need to be interpreted with caution since diagnosis of LV hypertrophy relied on electrocardiogram as the single method only, reduction of LV hypertrophy was related to improved prognosis. 1 In patients in whom LV hypertrophy persisted or developed despite antihypertensive treatment, a higher risk of subsequent cardiovascular events was found when compared with patients in whom LV mass remained normal or fell independent of other cardiovascular risk factors. 60 In a cooperative study from eastern Europe, 61 the occurrence of morbid events was strongly asso- 62 put light into this issue. Regression of LV hypertrophy was associated with a reduction of cardiovascular events. Confirmatory, after several years the worst prognosis was seen in patients receiving antihypertensive therapy with no reduction or even an increase in LV hypertrophy.
Most recently, Verdecchia et al 63 found that in essential hypertension, a reduction in LV mass during treatment is a favourable prognostic marker that predicts a lesser risk for subsequent cardiovascular morbid events. This association was independent of baseline LV mass, baseline clinic and ambulatory blood pressure, and degree of blood pressure reduction (Figure 2 ).
Conclusions and future implications
In the general population and in hypertensive patients, an increased LV mass has been shown to 63 predict cardiovascular complications more strongly than any other risk factor except advancing age. Conversely, a reduction of LV hypertrophy was associated with an improved prognosis.
In essential hypertension, most antihypertensive agents have been demonstrated to reduce LV hypertrophy. Regarding the available data from meta-analyses, both ACE-inhibitors and calcium channel blockers were more effective in reducing LV mass than ␤-blockers, with diuretics in the intermediate range. In particular, the rationale for blockade of the renin-angiotensin-aldosterone system as an effective measure to reduce LV hypertrophy is supported by numerous experimental data that documented growth stimulating effects of angiotensin II on the myocardium. Thus, it seems attractive to block the action of angiotensin II at the receptor level, and indeed some double-blind studies have indicated that angiotensin II AT 1 receptor blockers are more effective than ␤-blockers and diuretics in reducing LV hypertrophy. [88] [89] [90] A recently published study in 77 patients with essential hypertension demonstrated a significant reduction of LV mass after 22 months of losartan therapy, 88 although some of the initial studies with this drug were disappointing. 91, 92 Furthermore, in comparison with ␤-blockers, the AT 1 receptor blockers effected a greater reduction in LV mass than ␤-blockers in patients with essential hypertension. 89, 90 This was found for two compounds, irbesartan and valsartan, suggesting a class effect of the AT 1 receptor blockers rather than an effect of the specific compound examined in the studies. Whether the disparate ability of antihypertensive agents to reduce LV mass can be translated into better cardiovascular and overall prognosis of hypertensive patients certainly needs to be evaluated in further prospective controlled studies.
